NASDAQ:CLDX - Celldex Therapeutics Stock Price, Price Target & More

Question 1

What is Celldex Therapeutics' stock symbol?

Answer

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Question 2

How were Celldex Therapeutics' earnings last quarter?

Answer

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings results on Wednesday, March, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.08. The biopharmaceutical company earned $3.50 million during the quarter, compared to analyst estimates of $1.49 million. Celldex Therapeutics had a negative net margin of 1,157.96% and a negative return on equity of 47.36%. Celldex Therapeutics's quarterly revenue was up 87.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.30) EPS. View Celldex Therapeutics' Earnings History.

Question 3

When is Celldex Therapeutics' next earnings date?

Answer

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Celldex Therapeutics.

Question 4

What price target have analysts set for CLDX?

Answer

6 equities research analysts have issued twelve-month price objectives for Celldex Therapeutics' stock. Their forecasts range from $2.00 to $10.00. On average, they anticipate Celldex Therapeutics' share price to reach $4.50 in the next twelve months. View Analyst Ratings for Celldex Therapeutics.

Question 5

What are Wall Street analysts saying about Celldex Therapeutics stock?

Answer

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

1. Cowen Inc analysts commented, "We spoke with the company who clarified that it remains comfortable on what it has said about dosing for VY-AADC. We believe eventual dosing for the pivotal Phase 2/3 trial could come in between the doses used in the initial Phase 1b, i.e., between 1.5×10 12 to 4.5×10 12 vg in 900µl/putamen. Separately, VYGR has submitted a 510(k) device application in Mar-18 for its own Guide (V-TAG) that could serve as an alternative to the ClearPoint magnetic resonance imaging (MRI) compatible device used in the procedures so far; 10-K expected a V- TAG filing in 1H18. As such, we view this pullback as a particularly good opportunity to BUY this volatile stock." (5/10/2018)
2. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline received a major setback with failure of its lead pipeline candidate, glembatumumab vedotin, in breast cancer study. Following the failure, the company discontinued development of the candidate across all indications. With no approved products, further pipeline setbacks will severely impact Celldex. Celldex is now focusing on other promising candidates in its pipeline including varlilumab. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, Celldex depends entirely on product development, licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Also, shares of the company have underperformed the industry so far this year. Loss estimates have narrowed ahead of Q1 results. Clovis has a positive record of earnings surprises in the recent quarters." (5/8/2018)
3. Cantor Fitzgerald analysts commented, "Glemba is a Miss. The METRIC trial evaluating metastatic TNBC patients that overexpress gpNMB versus capecitibine did not achieve statistical significance, with glemba-treated patients experiencing PFS of 2.7 months versus 2.6 months for capecitibine, p=0.76. Additionally, significance was not achieved for key secondary endpoints of OR (overall response), DoR (Duration of Response) or OS (Overall Survival)." (4/17/2018)

Question 6

Are investors shorting Celldex Therapeutics?

Answer

Celldex Therapeutics saw a drop in short interest during the month of April. As of April 30th, there was short interest totalling 8,111,748 shares, a drop of 22.3% from the April 13th total of 10,445,637 shares. Based on an average daily volume of 8,499,808 shares, the short-interest ratio is presently 1.0 days. Approximately 5.7% of the shares of the company are short sold.

Question 7

Who are some of Celldex Therapeutics' key competitors?

Answer

Some companies that are related to Celldex Therapeutics include Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), ARCA biopharma (ABIO), GeneNews (GNWSF), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).

Question 8

Who are Celldex Therapeutics' key executives?

Answer

Celldex Therapeutics' management team includes the folowing people:

Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 56)
Dr. Tibor Keler Ph.D., Founder, Chief Scientific Officer and Exec. VP (Age 59)
Ms. Elizabeth Crowley, Chief Product Devel. Officer and Sr. VP (Age 46)
Mr. Sam Martin, Sr. VP, CFO, Principal Accounting Officer & Treasurer
Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin.

Question 9

Has Celldex Therapeutics been receiving favorable news coverage?

Answer

Media headlines about CLDX stock have been trending somewhat positive on Friday, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Question 10

Who are Celldex Therapeutics' major shareholders?

Answer

Celldex Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.04%), Dimensional Fund Advisors LP (2.91%), TSP Capital Management Group LLC (1.00%), JPMorgan Chase & Co. (0.69%), State of Wisconsin Investment Board (0.51%) and Schwab Charles Investment Management Inc. (0.40%). View Institutional Ownership Trends for Celldex Therapeutics.

Question 11

Which institutional investors are selling Celldex Therapeutics stock?

Answer

CLDX stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Celldex Therapeutics.

Question 12

Which institutional investors are buying Celldex Therapeutics stock?

Answer

CLDX stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, JPMorgan Chase & Co., BlackRock Inc. and TSP Capital Management Group LLC. View Insider Buying and Selling for Celldex Therapeutics.

Question 13

How do I buy shares of Celldex Therapeutics?

Answer

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 14

What is Celldex Therapeutics' stock price today?

Answer

One share of CLDX stock can currently be purchased for approximately $0.6337.

Question 15

How big of a company is Celldex Therapeutics?

Answer

Celldex Therapeutics has a market capitalization of $94.60 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-93,030,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Celldex Therapeutics employs 197 workers across the globe.

Question 16

How can I contact Celldex Therapeutics?

Answer

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		400 (Vote Outperform)
Underperform Votes:		205 (Vote Underperform)
Total Votes:		605

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Hold	Buy	Buy
Consensus Rating Score:	2.50	2.43	2.83	2.80
Ratings Breakdown:	0 Sell Rating(s) 3 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$4.50	$4.50	$8.1250	$7.50
Price Target Upside:	610.12% upside	491.33% upside	237.14% upside	172.73% upside

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/17/2018	HC Wainwright	Set Price Target	Buy	$2.00	Low
5/10/2018	Cowen	Reiterated Rating	Hold		Low
4/17/2018	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$3.00	Low
3/8/2018	Leerink Swann	Reiterated Rating	Market Perform ➝ Market Perform	$4.00 ➝ $3.00	High
12/6/2017	WBB Securities	Reiterated Rating	Buy	$10.00	Low
6/29/2017	Aegis	Reiterated Rating	Buy		Medium
5/11/2017	Jefferies Group	Reiterated Rating	Hold	$4.00 ➝ $3.50	High
11/10/2016	Roth Capital	Reiterated Rating	Buy	$7.00	N/A
11/8/2016	Wedbush	Reiterated Rating	Neutral	$3.00	N/A
10/4/2016	Brean Capital	Initiated Coverage	Buy	$16.00	N/A

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.20)	($0.19)	($0.20)
Q2 2018	2	($0.21)	($0.20)	($0.21)
Q3 2018	2	($0.27)	($0.22)	($0.25)
Q4 2018	2	($0.39)	($0.24)	($0.32)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		($0.20)					N/A
3/7/2018	Q4 2017	($0.25)	($0.17)	$1.49 million	$3.50 million	View	Listen
11/7/2017	Q3 2017	($0.27)	($0.20)	$1.30 million	$3.90 million	View	N/A
8/8/2017	Q2 2017	($0.28)	($0.23)	$1.21 million	$3.83 million	View	Listen
5/9/2017	Q1 2017	($0.2850)	($0.28)	$0.57 million	$1.53 million	View	N/A
3/14/2017	Q4 2016	($0.34)	($0.30)	$1.10 million	$1.87 million	View	Listen
11/7/2016	Q3 2016	($0.33)	($0.29)	$1.09 million	$2.20 million	View	N/A
8/8/2016	Q2	($0.34)	($0.32)	$0.96 million	$1.39 million	View	Listen
5/5/2016	Q1 16	($0.35)	($0.35)	$1.06 million	$1.30 million	View	N/A
2/25/2016	Q415	($0.35)	($0.33)	$0.80 million	$1.80 million	View	Listen
11/5/2015	Q3	($0.35)	($0.32)	$1.02 million	$1.03 million	View	N/A
8/10/2015	Q215	($0.34)	($0.33)	$0.51 million	$2.18 million	View	Listen
4/29/2015	Q115	($0.36)	($0.33)	$0.52 million	$0.49 million	View	N/A
2/24/2015	Q314	($0.35)	($0.36)	$0.49 million	$1.50 million	View	N/A
11/4/2014	Q3	($0.33)	($0.31)	$0.43 million	$1.10 million	View	N/A
8/6/2014	Q214	($0.31)	($0.32)	$0.38 million	$0.60 million	View	N/A
5/1/2014	Q1 2014	($0.26)	($0.33)	$0.34 million	$0.40 million	View	N/A
3/3/2014	Q413	($0.28)	($0.27)	$0.27 million	$0.62 million	View	N/A
11/5/2013	Q313	($0.24)	($0.29)	$0.09 million	$1.00 million	View	N/A
8/6/2013	Q2 2013	($0.22)	($0.24)	$1.57 million	$0.97 million	View	N/A
5/2/2013	Q1 2013	($0.22)	($0.23)	$2.65 million	$2.41 million	View	N/A
3/7/2013	Q4 2012	($0.25)	($0.27)	$2.45 million	$3.65 million	View	N/A
11/1/2012	Q312	($0.24)	($0.25)	$2.07 million	$3.11 million	View	N/A
8/10/2012		($0.25)	($0.23)			View	N/A
5/3/2012		($0.25)	($0.27)			View	N/A
3/7/2012		($0.26)	($0.29)			View	N/A
11/2/2011	Q3 2011	($0.26)	($0.27)			View	N/A
8/3/2011	Q2 2011	($0.28)	($0.27)			View	N/A
5/4/2011	Q1 2011	($0.30)	($0.30)			View	N/A
3/3/2011	Q4 2010	$0.21	($0.24)			View	N/A
11/2/2010	Q3 2010	($0.33)	($0.29)			View	N/A
8/4/2010	Q2 2010	($0.26)	($0.30)			View	N/A
5/4/2010	Q1 2010	($0.26)	($0.16)			View	N/A
3/4/2010	Q4 2009	($0.29)	($0.27)			View	N/A
11/4/2009	Q3 2009	($0.56)	($0.45)			View	N/A
8/5/2009	Q2 2009	($0.47)	($0.55)			View	N/A
5/5/2009	Q1 2009	($0.46)	($0.49)			View	N/A
2/27/2009	Q4 2008	($0.54)	($0.47)			View	N/A
11/5/2008	Q3 2008	($0.41)	($0.50)			View	N/A
8/6/2008	Q2 2008	($0.56)	($0.67)			View	N/A
5/19/2008	Q1 2008	($0.67)	($0.73)			View	N/A
2/27/2008	Q4 2007		($0.84)			View	N/A

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/2/2016	Tibor Keler	VP	Buy	3,000	$3.32	$9,960.00	18,868
11/23/2015	Avery W. Catlin	CFO	Sell	25,000	$18.00	$450,000.00	35,109
8/25/2015	Larry Ellberger	Director	Buy	5,000	$14.00	$70,000.00	53,500
8/20/2015	Larry Ellberger	Director	Buy	5,000	$15.00	$75,000.00	48,500
8/18/2015	Larry Ellberger	Director	Buy	5,000	$15.95	$79,750.00	43,500
8/13/2015	Anthony S Marucci	CEO	Buy	5,800	$16.81	$97,498.00
8/13/2015	Larry Ellberger	Director	Buy	5,000	$16.59	$82,950.00
6/15/2015	Avery W Catlin	CFO	Sell	25,000	$24.59	$614,750.00
12/6/2013	Avery Catlin	CFO	Sell	183,333	$24.50	$4,491,658.50	14,109
12/6/2013	Larry Ellberger	Director	Sell	17,728	$24.50	$434,336.00	25,000

Date	Headline
	FY2018 Earnings Forecast for Celldex Therapeutics, Inc. (CLDX) Issued By Cantor Fitzgerald www.americanbankingnews.com - May 24 at 8:38 AM
	Celldex Therapeutics, Inc. (CLDX) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - May 21 at 1:47 PM
	Celldex (CLDX) Announces Presentations at ASCO www.streetinsider.com - May 17 at 5:41 PM
	Celldex Therapeutics (CLDX) Given a $2.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - May 17 at 3:09 PM
	Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - May 16 at 5:11 PM
	May Insights Into Healthcare Stocks: Celldex Therapeutics Inc (NASDAQ:CLDX) finance.yahoo.com - May 15 at 5:28 PM
	Contrasting Idexx Laboratories (IDXX) & Celldex Therapeutics (CLDX) www.americanbankingnews.com - May 13 at 9:47 AM
	Celldex Therapeutics, Inc. (CLDX) Sees Large Drop in Short Interest www.americanbankingnews.com - May 12 at 2:10 AM
	Celldex Trying To Regroup With Its Early-Stage Assets seekingalpha.com - May 11 at 5:24 PM
	Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down www.zacks.com - May 11 at 9:10 AM
	Zacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $2.03 Million www.americanbankingnews.com - May 11 at 2:04 AM
	Celldex Therapeutics (CLDX) Given Hold Rating at Cowen www.americanbankingnews.com - May 10 at 9:39 PM
	Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down finance.yahoo.com - May 10 at 5:27 PM
	Celldex Therapeutics Moves Forward After Glemba Clinical Failure finance.yahoo.com - May 10 at 5:27 PM
	BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84 www.reuters.com - May 10 at 8:52 AM
	Celldex: 1Q Earnings Snapshot finance.yahoo.com - May 10 at 8:52 AM
	Celldex Provides Corporate Update and Reports First Quarter 2018 Results finance.yahoo.com - May 10 at 8:52 AM
	Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Earnings of -$0.17 Per Share www.americanbankingnews.com - May 9 at 9:14 PM
	Celldex Therapeutics (CLDX) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - May 8 at 3:23 PM
	Celldex Therapeutics (CLDX) Lifted to Sell at ValuEngine www.americanbankingnews.com - May 3 at 10:19 PM
	What's in Store for Celldex (CLDX) This Earnings Season? finance.yahoo.com - May 3 at 5:02 PM
	Contrasting Celldex Therapeutics (CLDX) & Oxford Immunotec Global (OXFD) www.americanbankingnews.com - May 3 at 3:10 AM
	Form 4 Celldex Therapeutics, For: May 01 Filed by: McMahon Gerald PhD www.streetinsider.com - May 2 at 5:12 PM
	Celldex Therapeutics (CLDX) Scheduled to Post Earnings on Monday www.americanbankingnews.com - April 30 at 8:54 AM
	Celldex Therapeutics, Inc. (CLDX) Short Interest Up 14.7% in April www.americanbankingnews.com - April 27 at 1:24 AM
	Biotech Analysis Central Pharma News: Takeda Raises Shire Bid, Daiichi Fails DMD Trial, Celldex Cuts 20% Of Workforce seekingalpha.com - April 26 at 5:00 PM
	Celldex Therapeutics, Inc. (CLDX) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 26 at 1:27 PM
	BRIEF-Celldex Therapeutics Approves Workforce Reduction www.reuters.com - April 24 at 5:16 PM
	Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $2.03 Million www.americanbankingnews.com - April 24 at 3:04 AM
	Is It Game Over for Celldex? finance.yahoo.com - April 23 at 4:56 PM
	Cantor Fitzgerald Brokers Reduce Earnings Estimates for Celldex Therapeutics, Inc. (CLDX) www.americanbankingnews.com - April 23 at 2:48 AM
	Celldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.17 Per Share www.americanbankingnews.com - April 22 at 11:15 AM
	Celldex (CLDX) Says Data from Multiple Programs Presented at AACR www.streetinsider.com - April 21 at 5:00 PM
	Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting ... globenewswire.com - April 20 at 5:03 PM
	3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise seekingalpha.com - April 19 at 8:42 AM
	Jefferies Group Weighs in on Celldex Therapeutics, Inc.'s FY2021 Earnings (CLDX) www.americanbankingnews.com - April 19 at 7:38 AM
	Celldex Tumbles On Phase 2 Trial Failure; Is There Any Value Left? seekingalpha.com - April 18 at 5:22 PM
	Celldex's Phase II Breast Cancer Study Fails, Shares Plunge finance.yahoo.com - April 17 at 5:33 PM
	Celldex's Phase II Breast Cancer Study Fails, Shares Plunge finance.yahoo.com - April 17 at 5:33 PM
	Celldex Therapeutics (CLDX) Stock Rating Lowered by Cantor Fitzgerald www.americanbankingnews.com - April 17 at 11:04 AM
	Celldex Therapeutics (CLDX) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - April 16 at 8:40 PM
	CLDX Apr 2018 5.000 put finance.yahoo.com - April 16 at 5:02 PM
	Why Celldex Therapeutics Is Getting Crushed 247wallst.com - April 16 at 5:02 PM
	Why Celldex Therapeutics Stock Is Cratering Today finance.yahoo.com - April 16 at 5:02 PM
	Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform www.americanbankingnews.com - April 16 at 1:21 PM
	Celldex Therapeutics (CLDX) Downgraded by HC Wainwright to Buy www.americanbankingnews.com - April 16 at 12:05 PM
	Celldex's lead candidate flunks breast cancer study; shares down 51% premarket seekingalpha.com - April 16 at 8:39 AM
	Celldex To Discontinue Glembatumumab Vedotin Program Across All Indications www.nasdaq.com - April 16 at 8:39 AM
	Celldex's stock plummets toward record low after failed drug study finance.yahoo.com - April 16 at 8:39 AM
	Celldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint finance.yahoo.com - April 16 at 8:39 AM

NASDAQ:CLDX - Celldex Therapeutics Stock Price, Price Target & More

About Celldex Therapeutics (NASDAQ:CLDX)

Receive CLDX News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

What is Celldex Therapeutics' stock symbol?

How were Celldex Therapeutics' earnings last quarter?

When is Celldex Therapeutics' next earnings date?

What price target have analysts set for CLDX?

What are Wall Street analysts saying about Celldex Therapeutics stock?

Are investors shorting Celldex Therapeutics?

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Has Celldex Therapeutics been receiving favorable news coverage?

Who are Celldex Therapeutics' major shareholders?

Which institutional investors are selling Celldex Therapeutics stock?

Which institutional investors are buying Celldex Therapeutics stock?

How do I buy shares of Celldex Therapeutics?

What is Celldex Therapeutics' stock price today?

How big of a company is Celldex Therapeutics?

How can I contact Celldex Therapeutics?

MarketBeat Community Rating for Celldex Therapeutics (CLDX)

Analyst Ratings

Celldex Therapeutics (NASDAQ:CLDX) Price Target and Consensus Rating

Celldex Therapeutics (NASDAQ:CLDX) Consensus Price Target History

Celldex Therapeutics (NASDAQ:CLDX) Analyst Ratings History

Earnings

Celldex Therapeutics (NASDAQ:CLDX) Earnings History and Estimates Chart

Celldex Therapeutics (NASDAQ:CLDX) Earnings Estimates

Celldex Therapeutics (NASDAQ CLDX) Earnings History by Quarter

Dividends

Celldex Therapeutics (NASDAQ:CLDX) Dividend History by Quarter

Insider Trades

Celldex Therapeutics (NASDAQ CLDX) Insider Trading and Institutional Ownership History

Celldex Therapeutics (NASDAQ CLDX) Insider Trading History

Headlines

Celldex Therapeutics (NASDAQ CLDX) News Headlines

SEC Filings

Celldex Therapeutics (NASDAQ:CLDX) SEC Filings

Social Media

Financials

Celldex Therapeutics (NASDAQ:CLDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celldex Therapeutics (NASDAQ CLDX) Stock Chart for Friday, May, 25, 2018